Caption: Structure of a HIV capsid (Left) Central slice view of a HIV virus-like particle with pore-forming toxin on the membrane (Middle) Atomic model of a HIV capsid (Right) Density map of HIV ...

Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its ...

More information: Jan Philipp Kreysing et al, Passage of the HIV capsid cracks the nuclear pore, Cell (2025). DOI: 10.1016/j.cell.2024.12.008 Provided by Max Planck Society ...

An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Caption The genetic material of the HIV virus is encased in multiple structures that hide it from the host immune system. The capsid, in blue, protects the virus after it enters a cell and ...

To start the simulations, a structural model of the HIV-1 M capsid first had to be produced with CYPA, which was then used to generate the other complexes for HIV-N, HIV-O, and HIV-P as well as ...

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.

Sunlenca – based on HIV capsid inhibitor lenacapavir – is intended as an add-on to current treatment for the infection. In trials, 81% of participants taking the regimen achieved HIV RNA ...

Lenacapavir, however, is the first drug to disrupt the protective capsid layer surrounding HIV's genetic material (RNA), blocking the virus's ability to reproduce and be transmitted from person to ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.